Ketan Paranjape VP

Ketan is Vice President of Business Development at Akiri and a Managing Director at Health2047. As the former General Manager of Life Sciences and Analytics at Intel Corporation, Ketan is a global health and life sciences business leader with a track record of identifying new businesses, product and solution development, creating partnerships, and delivering exceptional financial results through sales and marketing initiatives. During his 19-year tenure at Intel, Ketan has served as Head of Product and Engineering on a variety of cutting-edge technologies and as both Technical Advisor and Chief of Staff to Intel’s Chief Technology Officer. Additionally, Ketan has been a member of the U.S. Health IT Standards Committee Precision Medicine Task Force, AAAS-FBI-UNICRI Project on Life Sciences and National and Transnational Security, International Telecommunication Union’s Global Cybersecurity Working Group, and World Health Organization’s Experts Working Group on eHealth. He holds MS degrees in Electrical Engineering and Computer Sciences from the University of Wisconsin and an MBA from the University of Oregon. Ketan also completed the Stanford Executive Program and coursework in Healthcare Management at the Harvard School of Public Health. He is an Honorary Research Fellow at the Imperial College London and Technical Advisor in Artificial Intelligence at Lee Kong Chian School of Medicine Singapore.

Mark Bagnall CFO

Mark is CFO at Akiri, bringing his biotech expertise in rare and metabolic diseases and in clinical diagnostics. Previously, Mark co-founded Naia Pharmaceuticals, where he developed two new pharmaceutical development companies targeting both mature and emerging markets. He has served as CFO and COO of several public and private biotech companies. Mark is a member of the Board of Directors of medical diagnostic company Ativa Medical, Inc., and Chairman of the Board of infectious disease diagnostics company XCR Dx. As President and CEO at Genturadx, Mark restructured and internationally relocated the organization, growing the team by 900 percent before acquisition. He earned his BS in Finance from UC Berkeley’s Walter A. Haas School of Business.

Daphne Li COO

Daphne is COO at Akiri and Managing Director of Business Acceleration at Health2047. Passionate about scaling companies in all stages of the business life spectrum, Daphne has helped launch and scale startups as well as re-position Fortune 500 brands. Prior, Daphne was Senior Vice President of Enterprise at SaaS platform provider Upwork, where she was responsible for its enterprise business and top 3,500 marketplace clients. As former Chief Revenue Officer at enterprise social collaboration SaaS software provider Convo.com, Daphne grew client networks over 40 percent quarter over quarter. Prior to her tenure at Convo.com, Daphne served as Chief Operations Officer of residential solar company Sungevity where she grew sales by 24 percent. Daphne’s other professional experience includes posts such as Vice President of Marketing and Product Management at ADP, Director of Strategy for Apple’s education group, and Chief Strategy Officer and Vice President of Marketing for DoveBid. She began her career with Bain & Company’s business acceleration group. Daphne earned both an MBA and BA in Economics from Stanford.

Douglass Given MD, PhD CEO

An internist and infectious diseases doctor by background, Doug has been a global corporate and operating executive at Lilly, Monsanto, Schering Plough and Mallinckrodt, a serial entrepreneur, and a venture capitalist. He led five biotech companies as CEO, including Progenitor (NASDAQ:PGEN), NeoRx (NASDAQ:NERX), Via Pharmaceuticals (NASDAQ:VIAP), Vivaldi Biosciences Inc. and Mercator Genetics Inc. Doug is Managing Partner at Health2047 Capital Partners. Doug served as Health2047 Inc.’s Chief Executive from its founding in August of 2015 until January 2018. Previously, he spent more than a decade in venture capital as an Investment Partner and General Partner at life sciences investor Bay City Capital LLC through five sequential life sciences general funds and two sector-specific funds; he was associated with the partnership from 1999-2015. An experienced board member, Doug currently serves as a Director at Health2047 Inc. and board Chair at both Akiri Inc. and Arrowhead Pharmaceuticals Inc. He recently served as board Chair and CEO at Vivaldi Biosciences Inc. He serves on advisory boards at the University of Chicago Medicine, Johns Hopkins Bloomberg School of Public Health, Stanford Medicine, Harvard School of Public Health, and The Houston Methodist Research Institute. Doug received MD and PhD (Virology) degrees from the University of Chicago, an MBA from the Wharton School at the University of Pennsylvania, was a Clinical and Research Fellow at Massachusetts General Hospital and Harvard Medical School, and an Attending Physician and professor at Indiana University School of Medicine.